BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog 2016;8:42. [PMID: 27625705 DOI: 10.1186/s13099-016-0124-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J. Monocytes and Macrophages as Viral Targets and Reservoirs. Int J Mol Sci 2018;19:E2821. [PMID: 30231586 DOI: 10.3390/ijms19092821] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 16.5] [Reference Citation Analysis]
2 Hartmann P. Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Front Physiol 2022;13:893074. [DOI: 10.3389/fphys.2022.893074] [Reference Citation Analysis]
3 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
6 Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 2018;67:878-80. [PMID: 29718134 DOI: 10.1093/cid/ciy208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep 2018;8:8210. [PMID: 29844325 DOI: 10.1038/s41598-018-26509-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
8 Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ding H, Yi X, Zhang X, Wang H, Liu H, Mou WW. Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders. Front Cell Infect Microbiol 2021;11:572752. [PMID: 34790583 DOI: 10.3389/fcimb.2021.572752] [Reference Citation Analysis]
10 Altveş S, Yildiz HK, Vural HC. Interaction of the microbiota with the human body in health and diseases. Biosci Microbiota Food Health 2020;39:23-32. [PMID: 32328397 DOI: 10.12938/bmfh.19-023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
11 Reid M, Ma Y, Scherzer R, Price JC, French AL, Huhn GD, Plankey MW, Peters M, Grunfeld C, Tien PC. Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus. J Infect Dis 2018;217:1289-97. [PMID: 29304196 DOI: 10.1093/infdis/jix688] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
12 Shivaji S. Connect between gut microbiome and diseases of the human eye. J Biosci 2019;44. [DOI: 10.1007/s12038-019-9931-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
13 Pérez-Matute P, Íñiguez M, Villanueva-Millán MJ, Recio-Fernández E, Vázquez AM, Sánchez SC, Morano LE, Oteo JA. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.Eur J Intern Med. 2019;67:47-58. [PMID: 31221551 DOI: 10.1016/j.ejim.2019.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
14 Wu T, Li F, Chen Y, Wei H, Tian Z, Sun C, Sun R. CD4+ T Cells Play a Critical Role in Microbiota-Maintained Anti-HBV Immunity in a Mouse Model. Front Immunol. 2019;10:927. [PMID: 31114580 DOI: 10.3389/fimmu.2019.00927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Zahran SA, Ali-Tammam M, Ali AE, Aziz RK. Compositional variation of the human fecal microbiome in relation to azo-reducing activity: a pilot study. Gut Pathog 2021;13:58. [PMID: 34625106 DOI: 10.1186/s13099-021-00454-0] [Reference Citation Analysis]
16 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
17 Tamanai-Shacoori Z, Le Gall-David S, Moussouni F, Sweidan A, Polard E, Bousarghin L, Jolivet-Gougeon A. SARS-CoV-2 and Prevotella spp.: friend or foe? A systematic literature review. J Med Microbiol 2022;71. [PMID: 35511246 DOI: 10.1099/jmm.0.001520] [Reference Citation Analysis]
18 Bai L, Zhou P, Li D, Ju X. Changes in the gastrointestinal microbiota of children with acute lymphoblastic leukaemia and its association with antibiotics in the short term. J Med Microbiol 2017;66:1297-307. [PMID: 28855025 DOI: 10.1099/jmm.0.000568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
19 Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, Noureddin M, Ayoub WS, Durazo F, Benhammou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S. Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study. Hepatol Res 2018;48:1108-17. [PMID: 29923681 DOI: 10.1111/hepr.13207] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
20 Jia W, Rajani C, Xu H, Zheng X. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. Protein Cell 2021;12:374-93. [PMID: 32797354 DOI: 10.1007/s13238-020-00748-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yuan L, Hensley C, Mahsoub HM, Ramesh AK, Zhou P. Microbiota in viral infection and disease in humans and farm animals. Prog Mol Biol Transl Sci 2020;171:15-60. [PMID: 32475521 DOI: 10.1016/bs.pmbts.2020.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
22 Kalyana Chakravarthy S, Jayasudha R, Ranjith K, Dutta A, Pinna NK, Mande SS, Sharma S, Garg P, Murthy SI, Shivaji S. Alterations in the gut bacterial microbiome in fungal Keratitis patients. PLoS One 2018;13:e0199640. [PMID: 29933394 DOI: 10.1371/journal.pone.0199640] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
23 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
24 Martynov V, Havryliuk V, Skliar T, Sokolova I. Comparative analysis of the composition of intestinal microbiome in patients with liver diseases. ScienceRise: Biological Science 2020;0:15-22. [DOI: 10.15587/2519-8025.2020.192721] [Reference Citation Analysis]
25 Dong TS, Jacobs JP, Hussain SK. Microbial Profiles of Cirrhosis in the Human Small Intestine. Curr Gastroenterol Rep 2019;21:50. [PMID: 31444636 DOI: 10.1007/s11894-019-0717-2] [Reference Citation Analysis]
26 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lotfy MM, Hassan HM, Hetta MH, El-gendy AO, Mohammed R. Di-(2-ethylhexyl) Phthalate, a major bioactive metabolite with antimicrobial and cytotoxic activity isolated from River Nile derived fungus Aspergillus awamori. Beni-Suef University Journal of Basic and Applied Sciences 2018;7:263-9. [DOI: 10.1016/j.bjbas.2018.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, Ueda R, Aoyagi H, Tanaka S, Kiyono H, Matano T, Aizaki H, Yoshio S, Mita E, Muramatsu M, Kanto T, Tsutsumi T, Yotsuyanagi H. Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. Viruses 2021;13:2101. [PMID: 34696531 DOI: 10.3390/v13102101] [Reference Citation Analysis]
30 Wang Y, Pan CQ, Xing H. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. Biomed Res Int 2019;2019:9726786. [PMID: 31886272 DOI: 10.1155/2019/9726786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
31 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
32 Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. Front Pharmacol 2020;11:390. [PMID: 32372951 DOI: 10.3389/fphar.2020.00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
33 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
34 Tariq R, Wahab A, Singal AK. Editorial: direct anti-viral agents, hepatitis C virus eradication, and gut-liver axis-another mechanistic piece to the puzzle. Aliment Pharmacol Ther 2018;48:1321-2. [PMID: 30488623 DOI: 10.1111/apt.15047] [Reference Citation Analysis]
35 Yildiz S, Mazel-Sanchez B, Kandasamy M, Manicassamy B, Schmolke M. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome. 2018;6:9. [PMID: 29321057 DOI: 10.1186/s40168-017-0386-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 21.8] [Reference Citation Analysis]
36 Allali I, Abotsi RE, Tow LA, Thabane L, Zar HJ, Mulder NM, Nicol MP. Human microbiota research in Africa: a systematic review reveals gaps and priorities for future research. Microbiome 2021;9:241. [PMID: 34911583 DOI: 10.1186/s40168-021-01195-7] [Reference Citation Analysis]
37 Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y. Gut Dysbiosis Associated With Hepatitis C Virus Infection.Clin Infect Dis. 2018;67:869-877. [PMID: 29718124 DOI: 10.1093/cid/ciy205] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 23.3] [Reference Citation Analysis]
38 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
40 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
41 Li N, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019;10:1551. [PMID: 31333675 DOI: 10.3389/fimmu.2019.01551] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 26.7] [Reference Citation Analysis]
42 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]
43 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, Gasbarrini A, Pompili M. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11. [PMID: 30345704 DOI: 10.1111/apt.15004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
45 Mohieldeen K, Hamoda SAF, Ahmed SM, Najeeb A, Ellakany WI. Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00147-y] [Reference Citation Analysis]
46 Sadiq FA. Is it time for microbiome-based therapies in viral infections? Virus Res 2021;291:198203. [PMID: 33132161 DOI: 10.1016/j.virusres.2020.198203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
47 Mobeen F, Sharma V, Tulika P. Enterotype Variations of the Healthy Human Gut Microbiome in Different Geographical Regions. Bioinformation 2018;14:560-73. [PMID: 31223215 DOI: 10.6026/97320630014560] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
48 Taylor BC, Weldon KC, Ellis RJ, Franklin D, Groth T, Gentry EC, Tripathi A, McDonald D, Humphrey G, Bryant M, Toronczak J, Schwartz T, Oliveira MF, Heaton R, Grant I, Gianella S, Letendre S, Swafford A, Dorrestein PC, Knight R. Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome. mSystems 2020;5:e00465-20. [PMID: 32994287 DOI: 10.1128/mSystems.00465-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection. J Infect Dis 2021:jiab094. [PMID: 33598686 DOI: 10.1093/infdis/jiab094] [Reference Citation Analysis]
50 Hamdi Y, Zass L, Othman H, Radouani F, Allali I, Hanachi M, Okeke CJ, Chaouch M, Tendwa MB, Samtal C, Mohamed Sallam R, Alsayed N, Turkson M, Ahmed S, Benkahla A, Romdhane L, Souiai O, Tastan Bishop Ö, Ghedira K, Mohamed Fadlelmola F, Mulder N, Kamal Kassim S. Human OMICs and Computational Biology Research in Africa: Current Challenges and Prospects. OMICS 2021;25:213-33. [PMID: 33794662 DOI: 10.1089/omi.2021.0004] [Reference Citation Analysis]
51 Wang F, Cui Q, Zeng Y, Chen P. [Gut microbiota-an important contributor to liver diseases]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:595-600. [PMID: 32895142 DOI: 10.12122/j.issn.1673-4254.2020.04.23] [Reference Citation Analysis]
52 Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res 2020;6:5. [PMID: 32582865 DOI: 10.20517/2394-5079.2019.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
53 Mazel-Sanchez B, Yildiz S, Schmolke M. Ménage à trois: Virus, Host, and Microbiota in Experimental Infection Models. Trends Microbiol 2019;27:440-52. [PMID: 30638775 DOI: 10.1016/j.tim.2018.12.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
54 Grąt M, Grąt K, Krawczyk M, Lewandowski Z, Krasnodębski M, Masior Ł, Patkowski W, Zieniewicz K. Post-hoc analysis of a randomized controlled trial on the impact of pre-transplant use of probiotics on outcomes after liver transplantation. Sci Rep 2020;10:19944. [PMID: 33204004 DOI: 10.1038/s41598-020-76994-3] [Reference Citation Analysis]
55 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
57 Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.ACS Infect Dis. 2021;7:1059-1068. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
58 Dumitru IM, Dumitru E, Rugina S, Tuta LA. Toxic Megacolon - A Three Case Presentation. J Crit Care Med (Targu Mures) 2017;3:39-44. [PMID: 29967870 DOI: 10.1515/jccm-2017-0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
59 Castillo-Dela Cruz P, Wanek AG, Kumar P, An X, Elsegeiny W, Horne W, Fitch A, Burr AHP, Gopalakrishna KP, Chen K, Methé BA, Canna SW, Hand TW, Kolls JK. Intestinal IL-17R Signaling Constrains IL-18-Driven Liver Inflammation by the Regulation of Microbiome-Derived Products. Cell Rep 2019;29:2270-2283.e7. [PMID: 31747600 DOI: 10.1016/j.celrep.2019.10.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
60 Baker SS, Baker RD. Gut Microbiota and Liver Injury (II): Chronic Liver Injury. Adv Exp Med Biol 2020;1238:39-54. [PMID: 32323179 DOI: 10.1007/978-981-15-2385-4_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
61 Ahmad MS, El-Gendy AO, Ahmed RR, Hassan HM, El-Kabbany HM, Merdash AG. Exploring the Antimicrobial and Antitumor Potentials of Streptomyces sp. AGM12-1 Isolated from Egyptian Soil. Front Microbiol 2017;8:438. [PMID: 28348553 DOI: 10.3389/fmicb.2017.00438] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
62 Hemeda AA, Ahmad Mohamed A, Aziz RK, Abdel-Hakeem MS, Ali-Tammam M. Impact of IL10, MTP, SOD2, and APOE Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4. Viruses 2021;13:714. [PMID: 33924242 DOI: 10.3390/v13040714] [Reference Citation Analysis]
63 Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017;11:813-9. [PMID: 28621554 DOI: 10.1080/17474124.2017.1343663] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
64 Wu S, Wang M, Zhang M, He JQ. Metabolomics and microbiomes for discovering biomarkers of antituberculosis drugs-induced hepatotoxicity. Arch Biochem Biophys 2022;:109118. [PMID: 34999018 DOI: 10.1016/j.abb.2022.109118] [Reference Citation Analysis]
65 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
66 Philips CA, Augustine P, Yerol PK, Ramesh GN, Ahamed R, Rajesh S, George T, Kumbar S. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8:87-99. [PMID: 32274349 DOI: 10.14218/jcth.2019.00035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Yan HM, Zhao HJ, Guo DY, Zhu PQ, Zhang CL, Jiang W. Gut microbiota alterations in moderate to severe acne vulgaris patients. J Dermatol 2018;45:1166-71. [PMID: 30101990 DOI: 10.1111/1346-8138.14586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
68 Gamal-AbdelNaser A, Mohammed WS, ElHefnawi M, AbdAllah M, Elsharkawy A, Zahran FM. The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. Oral Dis 2021. [PMID: 34396636 DOI: 10.1111/odi.14007] [Reference Citation Analysis]
69 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]